Intel
Incoming wire · every headline scored for the targets it names
Incoming wire · every headline scored for the targets it names
Salesforce-Braze Deal Draws Downgrades as Analysts Assess Acquisition Value
No targets blocked. Every unit is clear to engage.

No news trades open. Herald engages on the next strongly positive, material headline.
UNIT-01 · buys blocked: news veto (-0.6 "Nasdaq Down Over 600 Points; Amazon Shares Fall Following W…") until 2026-10-31T13:39Z
These Analysts Slash Their Forecasts On GE Aerospace After Q3 Results
Barclays Maintains Overweight on RTX, Raises Price Target to $235
Barclays Maintains Equal-Weight on Netflix, Lowers Price Target to $65
Barclays Maintains Overweight on AbbVie, Raises Price Target to $325
Elon Musk's Tesla-SpaceX Mega-Merger Could Create 'Most Unique Company in the World,' Says Analyst
Susquehanna Maintains Positive on Advanced Micro Devices, Raises Price Target to $620
'OpenAI To Bring AI Models To Google’s Cloud, In Further Expansion Beyond Microsoft' - CNBC
Netflix Stock Sinks To 52-Week Low - Here's Why
Abbott Reports Third-Quarter 2026 Financial Results
Abbott Announces Planned Separation of Nutrition Business
JPMorgan Chase Downgraded by MarketScreener
These Analysts Slash Their Forecasts On Netflix After Q3 Results
Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est
AT&T Inc. Reports Third-Quarter 2026 Financial Results and Raises 2026 Outlook
Abbott Laboratories Sees Q4 Adj EPS $1.62-$1.67 vs $1.64 Est
Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate
UNIT-01 · buys blocked: news veto (-0.6 "Meta Platforms Outlook Revised To Negative On Significant U…") until 2026-10-31T21:07Z